P3 1L Chemo vs Pembro Chemo NSCLC CB 202
Research payments
$301,962
Through program year 2024, $301,962 in research payments was reported against P3 1L Chemo vs Pembro Chemo NSCLC CB 202, across 38 payments, paid by Amgen Inc..
- Paid by
- Amgen Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $301,962 | 38 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Bob Li New York, NY Named on 3 payments
- James Stinchon Abington, PA Named on 2 payments
- Ferdinandos Skoulidis Houston, TX Named on 2 payments
- Nisha Sainani Boston, MA Named on 2 payments
- Jeffrey Clarke Durham, NC Named on 2 payments
- Frank Weinberg Chicago, IL Named on 2 payments
- James Schuster Cape Coral, FL Named on 2 payments
- Trevor Morrison Bronx, NY Named on 2 payments
- Martha Mapalo Albuquerque, NM Named on 2 payments
- Adam Lye Jeffersonville, IN Named on 2 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.